Ȩ Ä«Å×°í¸® ¸ÂÃãÇü½ÃÀåÁ¶»ç ±¹Á¦ÄÁÆÛ·±½º ±Û·Î¹ú ÆÄÆ®³Ê ¸ÞÀϸµ ¼­ºñ½º ȸ»ç¼Ò°³È¸»ç¼Ò°³ Contact Us
English Japaness Chinese
Ä«Å×°í¸®
ÆÄ¸Ó½´Æ¼Äà (4512)
°¨¿°Áúȯ (322)
°ñÁúȯ Ä¡·á (48)
´ç´¢º´ (164)
¹é½Å (169)
ºñ¸¸Ä¡·á/´ÙÀÌ¾îÆ® (49)
ºñó¹æ ÀǾàǰ (149)
¼öÀÇÇÐ (17)
½Å°æÁúȯ (179)
½Å¾à°³¹ß (1306)
¾ÏÄ¡·á (856)
¾à¹°Àü´Þ (179)
ÀǾàǰ ±ÔÁ¦È¯°æ (105)
Á¤½ÅÁúȯ (88)
Á¦³×¸¯ ÀǾàǰ (116)
Á¦¾àȸ»çºÐ¼® (488)
󹿾à (128)
Áö¿ªº°°Ë»ö
ÃâÆÇ»ç¿¡¼­ ã±â

ó¹æ¾à ½ÃÀåÁ¶»çº¸°í¼­

ó¹æ¾à ½ÃÀåÀ» Á¶»ç ºÐ¼®ÇÑ ÀÚ·á·Î ½ÃÀå ±Ô¸ð, »ê¾÷ ºÐ¼®, ÇâÈÄ ½ÃÀå ¿¹Ãø µîÀÇ ³»¿ëÀ» ´Ù·ç°í ÀÖ½À´Ï´Ù.
º¸°í¼­¿¡ µû¶ó¼­ ÁÖ¿ä ±â¾÷ ºÐ¼®, °æÀïȯ°æ ºÐ¼®, ¿¬±¸°³¹ß ÇöȲ, ¿µ¾÷ Àü·«, ±â¾÷ Á¦ÈÞ ÇöȲÀ» Æ÷ÇÔÇÏ´Â °æ¿ìµµ ÀÖ½À´Ï´Ù.

»ó¼¼ºÐ·ù
Á¦¸ñ°Ë»ö
1 - 25 ¸®ºä (Àüü£º 128 °Ç) Á¤·Ä Ç¥½Ã °Ç¼ö
»ùÇÃ
»óǰÄÚµå :223941
¾ËÃ÷ÇÏÀ̸Ӻ´, °üÀý¿°, ¾Ï, ½ÉÇ÷°üÁúȯ, ´ç´¢º´, ¹ß±âÀå¾Ö, ¾ÈÁúȯ, Å»¸ð, °íÄÝ·¹½ºÅ×·Ñ, °íÇ÷¾Ð, ½ÅÀ庴, °ñ´Ù°øÁõ, ÆÄŲ½¼º´, ³úÁ¹Áß, ÁÖ¸§¿¡ ´ëÇÑ Ã³¹æ¾à ÇöȲ°ú ÇâÈÄ Àü¸ÁÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 1,495
¹ßÇàÀÏ 2011³â 11¿ù
¸®¼­Ä¡»ç Fuji-Keizai U.S.A., Inc.
ÆäÀÌÁö¼ö 246 Pages
The World Market for Prescription Arthritis Treatments
»ùÇÃ
¿­¶÷ ¼­ºñ½º Á¦°ø
»óǰÄÚµå :225405
¼¼°èÀÇ °üÀý¿° 󹿾à(Prescription Arthritis Treatments) ½ÃÀå ÇöȲ°ú Àü¸ÁÀ» Á¶»ç ºÐ¼®Çϰí NSAID(ºñ½ºÅ×·ÎÀ̵å°è Ç׿°Áõ¼º ¾à¹°), DMARD(Áúȯ ¼ö½Ä¼º Ç×·ù¸¶Æ¼½º ¾à¹°), BRM(»ýü¹ÝÀÀÁ¶ÀýÁ¦) ¹× ¸é¿ª¾ïÁ¦Á¦ ºÎ¹®ÀÇ Á¦Ç° °³¿ä, ½ÃÀå ¿¹Ãø(-2016³â), Áö¿ª µ¿Çâ, °æÀï ±¸µµ, °üÀý¿° ó¹æ¾à ½ÃÀå¿¡ ´ëÇÑ °¢Á¾ ¿µÇâ¿äÀÎ ºÐ¼®, R&D µ¿Çâ, ÁÖ¿ä ±â¾÷ °³¿ä µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,500
¹ßÇàÀÏ 2011³â 11¿ù
¸®¼­Ä¡»ç Kalorama Information
ÆäÀÌÁö¼ö 4 Pages
Talactoferrin Alfa (NSCLC) - Analysis and Forecasts to 2020
»ùÇÃ
»óǰÄÚµå :222279
¼¼°èÀÇ ºñ¼Ò¼¼Æ÷ Æó¾Ï(NSCLC) ½ÃÀå °³¿ä¿Í ½ÃÀå Æ¯¼º, TNM ºÐ·ù¸¦ Á¶»ç ºÐ¼®Çϰí, Talactoferrin Alfa °³¿ä¿Í ÀÛ¿ë±â¼­, ÀÓ»ó½ÃÇè µ¿Çâ, ¸ÅÃâ ¿¹ÃøÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,000
¹ßÇàÀÏ 2011³â 10¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 35
Drugs for the Diseases of Aging: US Markets and Trends for Prescription Medicines Used Predominantly by Persons Age 50 and older
»ùÇÃ
»óǰÄÚµå :216967
50¼¼ ÀÌ»ó Àα¸°¡ ÁÖ·Î ÀÌȯÇÏ´Â Áúȯ, Áõ»ó¿¡ ´ëÇÑ Ã³¹æ¾à(Prescription Medicines) ½ÃÀåÀ» ºÐ¼®ÇÏ¿© ¹Ì±¹ ½ÃÀåÀ» Áß½ÉÀ¸·Î 2015³â±îÁöÀÇ ½ÃÀå ¿¹Ãø, ±âÁ¸ ¹× ½ÅÈï ¾àÁ¦ Á¦Á¶¾÷üÀÇ ÇÕº´ ¹× ¸Å¼ö µ¿Çâ, ¿¬±¸ °³¹ß °èȹ, º¥Ã³Ä³ÇÇÅРȰµ¿ µî¿¡ ´ëÇØ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 1,495
¹ßÇàÀÏ 2011³â 10¿ù
¸®¼­Ä¡»ç Fuji-Keizai U.S.A., Inc.
ÆäÀÌÁö¼ö 263 Pages
Autistic Disorder Therapeutics - Pipeline Assessment and Market Forecasts to 2018
»ùÇÃ
»óǰÄÚµå :217225
ÀÚÆóÀå¾ÖÀÇ °³¿ä¿Í Áø´Ü, Ä¡·á¹ý, Ä¡·áÁ¦ ½ÃÀåÀÇ ±Ô¸ð¿Í 2018³â±îÁöÀÇ ¿¹Ãø, ÁÖ¿ä ½ÃÀ庰 µ¿Çâ, °³¹ß ÆÄÀÌÇÁ¶óÀÎ, Âü¿©±â¾÷ °³¿ä µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,500
¹ßÇàÀÏ 2011³â 10¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 67
Comparative Analysis of Marketed Drugs in Major Indications - Patent Cliff to Set Off Intense Price Competition in High Volume Markets
»ùÇÃ
»óǰÄÚµå :212663
ÁÖ¿ä ÀûÀÀÀÇ ½ÃÆÇ ÀǾàǰ¿¡ ´ëÇØ ºÐ¼®ÇßÀ¸¸ç, ¾ÈÀü¼º, À¯È¿¼º, Ä¡·áºñ¿ë, ÃѸÅÃâ¾×À» ±â¹ÝÀ¸·Î ½ÃÆÇ ÀǾàǰÀ» ºñ±³ºÐ¼®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,500
¹ßÇàÀÏ 2011³â 08¿ù
¸®¼­Ä¡»ç GBI Research
ÆäÀÌÁö¼ö Pages: 195
Prescription Drug Patches to 2015: Products, Indications, Markets and Opportunities
»ùÇÃ
»óǰÄÚµå :209137
ó¹æ¾à ÆÐÄ¡(Prescription Drug Patches) ½ÃÀå¿¡ ´ëÇØ Á¶»ç ºÐ¼®Çϰí, °æÇÇÀû ¾à¹°Àü´Þ °³¿ä, ÆÐÄ¡ ±â¼ú µ¿Çâ, ½ÂÀÎ ¾àÁ¦ °³¿ä, ½ÃÀå ÁøÃâ ±â¾÷ °³¿ä µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,850
¹ßÇàÀÏ 2011³â 08¿ù
¸®¼­Ä¡»ç Greystone Research Associates
ÆäÀÌÁö¼ö  
»ùÇÃ
»óǰÄÚµå :214196
õ½Ä(Asthma) ¹× ¸¸¼º Æó¼â¼º ÆóÁúȯ(COPD) Ä¡·áÁ¦ ½ÃÀå¿¡ ´ëÇØ Á¶»ç ºÐ¼®Çϰí, 2011³â µ¿Çâ°ú 2021³â±îÁöÀÇ ¸ÅÃâ ¿¹Ãø, ½ÃÀå ±âȸ, ÁÖ¿ä ±â¾÷ÀÇ Àü¸Á µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,331
¹ßÇàÀÏ 2011³â 08¿ù
¸®¼­Ä¡»ç Visiongain
ÆäÀÌÁö¼ö  
Brivanib - Analysis and Market Forecasts from 2013 to 2020
»ùÇÃ
»óǰÄÚµå :217347
°£¾Ï Ä¡·áÁ¦ÀÎ BrivanibÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹Ãø, ½ÃÀåÀÇ Æ¯Â¡, °æÀï, ÆÄÀÌÇÁ¶óÀÎ Æò°¡ ºÐ¼®, ÇâÈÄÀÇ ½ÃÀå °æÀï µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,000
¹ßÇàÀÏ 2011³â 07¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 29
Linifanib - Assessment and Market Forecasts from 2013 to 2020
»ùÇÃ
»óǰÄÚµå :217346
°£¾Ï ½ÃÀåÀÇ °³¿ä¸¦ Á¶»çÇϰí, Ÿ°Ù Ä¡·áÁ¦ÀÎ Linifanib¿¡ ´ëÇÑ ÀÛ¿ë±â¼­, À§Çè-ÀÌÀÍ ½ºÄÚ¾î, ¸ÅÃâ ¿¹Ãø µîÀ» ºÐ¼®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,000
¹ßÇàÀÏ 2011³â 07¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 28
Ramucirumab - Analysis and Market Forecasts from 2014 to 2020
»ùÇÃ
»óǰÄÚµå :217345
°£¾Ï Ä¡·áÁ¦ÀÎ RamucirumabÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹Ãø, ½ÃÀåÀÇ Æ¯Â¡, °æÀï, ÆÄÀÌÇÁ¶óÀÎ Æò°¡ ºÐ¼®, ÇâÈÄÀÇ ½ÃÀå °æÀï µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,000
¹ßÇàÀÏ 2011³â 07¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 28
Tarceva - Analysis and Market Forecasts from 2013 to 2020
»ùÇÃ
»óǰÄÚµå :217344
°£¾Ï Ä¡·áÁ¦ÀÎ TarcevaÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹Ãø, ½ÃÀåÀÇ Æ¯Â¡, °æÀï, ÆÄÀÌÇÁ¶óÀÎ Æò°¡ ºÐ¼®, ÇâÈÄÀÇ ½ÃÀå °æÀï µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,000
¹ßÇàÀÏ 2011³â 07¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 27
Avastin (bevacizumab) - Analysis and Market Forecasts from 2016 to 2020
»ùÇÃ
»óǰÄÚµå :217328
°£¾Ï Ä¡·áÁ¦ÀÎ AvastinÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹Ãø, ½ÃÀåÀÇ Æ¯Â¡, °æÀï, ÆÄÀÌÇÁ¶óÀÎ Æò°¡ ºÐ¼®, ÇâÈÄÀÇ ½ÃÀå °æÀï µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,000
¹ßÇàÀÏ 2011³â 07¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 28
Nexavar - Analysis and Market Forecasts from 2007 to 2020
»ùÇÃ
»óǰÄÚµå :217321
°£¾Ï Ä¡·áÁ¦ÀÎ NexavarÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹Ãø, ½ÃÀåÀÇ Æ¯Â¡, °æÀï, ÆÄÀÌÇÁ¶óÀÎ Æò°¡ ºÐ¼®, ÇâÈÄÀÇ ½ÃÀå °æÀï µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,000
¹ßÇàÀÏ 2011³â 07¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 28
PrevOnco - Analysis and Market Forecasts from 2014 to 2020
»ùÇÃ
»óǰÄÚµå :217320
°£¾Ï Ä¡·áÁ¦ÀÎ PrevOncoÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹Ãø, ½ÃÀåÀÇ Æ¯Â¡, °æÀï, ÆÄÀÌÇÁ¶óÀÎ Æò°¡ ºÐ¼®, ÇâÈÄÀÇ ½ÃÀå °æÀï µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,000
¹ßÇàÀÏ 2011³â 07¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 27
Muparfostat - Analysis and Market Forecasts from 2017 to 2020
»ùÇÃ
»óǰÄÚµå :217318
°£¾Ï Ä¡·áÁ¦ÀÎ MuparfostatÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹Ãø, ½ÃÀåÀÇ Æ¯Â¡, °æÀï, ÆÄÀÌÇÁ¶óÀÎ Æò°¡ ºÐ¼®, ÇâÈÄÀÇ ½ÃÀå °æÀï µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,000
¹ßÇàÀÏ 2011³â 07¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 28
Thalidomide - Analysis and Market Forecasts from 2015 to 2020
»ùÇÃ
»óǰÄÚµå :217317
°£¾Ï Ä¡·áÁ¦ÀÎ ThalidomideÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹Ãø, ½ÃÀåÀÇ Æ¯Â¡, °æÀï, ÆÄÀÌÇÁ¶óÀÎ Æò°¡ ºÐ¼®, ÇâÈÄÀÇ ½ÃÀå °æÀï µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,000
¹ßÇàÀÏ 2011³â 07¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 27
Doxorubicin - Analysis and Market Forecasts from 2011 to 2020
»ùÇÃ
»óǰÄÚµå :217316
°£¾Ï Ä¡·áÁ¦ÀÎ DoxorubicinÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹Ãø, ½ÃÀåÀÇ Æ¯Â¡, °æÀï, ÆÄÀÌÇÁ¶óÀÎ Æò°¡ ºÐ¼®, ÇâÈÄÀÇ ½ÃÀå °æÀï µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,000
¹ßÇàÀÏ 2011³â 07¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 29
ThermoDox - Analysis and Market Forecasts from 2012 to 2020
»ùÇÃ
»óǰÄÚµå :217315
°£¾Ï Ä¡·áÁ¦ÀÎ ThermoDoxÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹Ãø, ½ÃÀåÀÇ Æ¯Â¡, °æÀï, ÆÄÀÌÇÁ¶óÀÎ Æò°¡ ºÐ¼®, ÇâÈÄÀÇ ½ÃÀå °æÀï µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,000
¹ßÇàÀÏ 2011³â 07¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 29
Miripla - Analysis and Market Forecasts from 2010 to 2020
»ùÇÃ
»óǰÄÚµå :217309
°£¾Ï Ä¡·áÁ¦ÀÎ MiriplaÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹Ãø, ½ÃÀåÀÇ Æ¯Â¡, °æÀï, ÆÄÀÌÇÁ¶óÀÎ Æò°¡ ºÐ¼®, ÇâÈÄÀÇ ½ÃÀå °æÀï µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,000
¹ßÇàÀÏ 2011³â 07¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 20
Veletri (epoprostenol) - Analysis and Forecasts from 2010 to 2020
»ùÇÃ
»óǰÄÚµå :217341
Æóµ¿¸Æ °íÇ÷¾Ð(PAH) Ä¡·áÁ¦ÀÎ Veletri(epoprostenol)ÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹Ãø, ½ÃÀåÀÇ Æ¯Â¡, °æÀï, ÆÄÀÌÇÁ¶óÀÎ Æò°¡ ºÐ¼®, ÇâÈÄÀÇ ½ÃÀå °æÀï µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,000
¹ßÇàÀÏ 2011³â 07¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 37
Tracleer (bosentan) - Analysis and Forecasts from 2002 to 2020
»ùÇÃ
»óǰÄÚµå :217340
Æóµ¿¸Æ °íÇ÷¾Ð(PAH) Ä¡·áÁ¦ÀÎ Tracleer(bosentan)ÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹Ãø, ½ÃÀåÀÇ Æ¯Â¡, °æÀï, ÆÄÀÌÇÁ¶óÀÎ Æò°¡ ºÐ¼®, ÇâÈÄÀÇ ½ÃÀå °æÀï µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,000
¹ßÇàÀÏ 2011³â 07¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 39
Revatio (sildenafil)- Analysis and Estimates from 2005 to 2020
»ùÇÃ
»óǰÄÚµå :217339
Æóµ¿¸Æ °íÇ÷¾Ð(PAH) Ä¡·áÁ¦ÀÎ Revatio (sildenafil)ÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹ÃøÀ» Á¶»çÇϰí, ½ÃÀå Æ¯Â¡, °æÀï, ÆÄÀÌÇÁ¶óÀÎ µîÀÇ Æò°¡ ºÐ¼®°ú ÇâÈÄ ½ÃÀå °æÀï »óȲÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,000
¹ßÇàÀÏ 2011³â 07¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 41
Letairis/Volibris (ambrisentan) - Analysis and Forecasts from 2007 to 2020
»ùÇÃ
»óǰÄÚµå :217337
Æóµ¿¸Æ °íÇ÷¾Ð(PAH) Ä¡·áÁ¦ÀÎ Letairis/Volibris(ambrisentan)ÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹Ãø, ½ÃÀåÀÇ Æ¯Â¡, °æÀï, ÆÄÀÌÇÁ¶óÀÎ Æò°¡ ºÐ¼®, ÇâÈÄÀÇ ½ÃÀå °æÀï µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,000
¹ßÇàÀÏ 2011³â 07¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 38
Ventavis (iloprost) - Analysis and Estimates from 2003 to 2017
»ùÇÃ
»óǰÄÚµå :217335
Æóµ¿¸Æ °íÇ÷¾Ð(PAH) Ä¡·áÁ¦ÀÎ Ventavis (iloprost)ÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹ÃøÀ» Á¶»çÇϰí, ½ÃÀå Æ¯Â¡, °æÀï, ÆÄÀÌÇÁ¶óÀÎ µîÀÇ Æò°¡ ºÐ¼®°ú ÇâÈÄ ½ÃÀå °æÀï »óȲÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,000
¹ßÇàÀÏ 2011³â 07¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 37